NASDAQ:DMACDiaMedica Therapeutics Stock Price, Forecast & News

DiaMedica Therapeutics' stock was trading at $4.00 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, DMAC shares have increased by 68.8% and is now trading at $6.75. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DiaMedica Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for DiaMedica Therapeutics.

DiaMedica Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for DiaMedica Therapeutics.

DiaMedica Therapeutics Inc (NASDAQ:DMAC) issued its quarterly earnings data on Wednesday, May, 13th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.28) by $0.09. View DiaMedica Therapeutics' earnings history.

2 brokerages have issued 12 month price objectives for DiaMedica Therapeutics' shares. Their forecasts range from $14.00 to $15.00. On average, they anticipate DiaMedica Therapeutics' stock price to reach $14.50 in the next year. This suggests a possible upside of 114.8% from the stock's current price. View analysts' price targets for DiaMedica Therapeutics.

News headlines about DMAC stock have been trending negative on Wednesday, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. DiaMedica Therapeutics earned a media sentiment score of -2.1 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news about DiaMedica Therapeutics.

DiaMedica Therapeutics saw a drop in short interest during the month of June. As of June 30th, there was short interest totaling 19,600 shares, a drop of 14.0% from the June 15th total of 22,800 shares. Based on an average daily volume of 71,000 shares, the short-interest ratio is presently 0.3 days. Approximately 0.2% of the company's shares are sold short. View DiaMedica Therapeutics' Current Options Chain.

Some companies that are related to DiaMedica Therapeutics include Avedro (AVDR), Spectrum Pharmaceuticals (SPPI), Aeglea Bio Therapeutics (AGLE), Organogenesis (ORGO), Liminal BioSciences (LMNL), Ovid Therapeutics (OVID), Avid Bioservices (CDMO), Albireo Pharma (ALBO), CytomX Therapeutics (CTMX), Seres Therapeutics (MCRB), TherapeuticsMD (TXMD), ANI Pharmaceuticals (ANIP), MannKind (MNKD), MEI Pharma (MEIP) and Kamada (KMDA). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other DiaMedica Therapeutics investors own include Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Amarin (AMRN), Oncolytics Biotech (ONCY), vTv Therapeutics (VTVT), Adamis Pharmaceuticals (ADMP), Crispr Therapeutics (CRSP), Seelos Therapeutics (SEEL) and Vaxart (VXRT).

(DMAC) raised $18 million in an IPO on Friday, December 7th 2018. The company issued 4,000,000 shares at a price of $4.00-$5.00 per share. Craig-Hallum Capital Group acted as the underwriter for the IPO.

DiaMedica Therapeutics trades on the NASDAQ under the ticker symbol "DMAC."

Shares of DMAC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of DMAC stock can currently be purchased for approximately $6.75.

DiaMedica Therapeutics has a market capitalization of $95.44 million and generates $500,000.00 in revenue each year. The company earns $-10,650,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. DiaMedica Therapeutics employs 9 workers across the globe.

The official website for DiaMedica Therapeutics is www.diamedica.com.

DiaMedica Therapeutics' mailing address is 2 CARLSON PARKWAY SUITE 260, MINNEAPOLIS MN, 55447. The company can be reached via phone at 763-312-6755 or via email at [email protected]